This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 27/1/211    most recent 01.ATV.0000249861.80471.96v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tsai, J. Articles by Adeli, K. Search for Related Content PubMed PubMed Citation Articles by Tsai, J. Articles by Adeli, K. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Genetics Home Reference Medline Plus Health Information Liver Cancer Hazardous Substances DB OLEIC ACID

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:211.)
© 2007 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

MEK–ERK Inhibition Corrects the Defect in VLDL Assembly in HepG2 Cells

Potential Role of ERK in VLDL-ApoB100 Particle Assembly

Julie Tsai; Wei Qiu; Rita Kohen-Avramoglu; Khosrow Adeli

From the Division of Clinical Biochemistry, Hospital for Sick Children, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada.

Correspondence to Khosrow Adeli, Division of Clinical Biochemistry, Hospital for Sick Children, University of Toronto, Ontario, Canada M5G 1X8. E-mail khosrow.adeli{at}sickkids.ca

Objective— Hepatic VLDL assembly is defective in HepG2 cells, resulting in the secretion of immature triglyceride-poor LDL-sized apoB particles. We investigated the mechanisms underlying defective VLDL assembly in HepG2 and have obtained evidence implicating the MEK–ERK pathway.

Methods and Results— HepG2 cells exhibited considerably higher levels of the ERK1/2 mass and activity compared with primary hepatocytes. Inhibition of ERK1/2 using the MEK1/MEK2 inhibitor, U0126 (but not the inactive analogue) led to a significant increase in apoB secretion. In the presence of oleic acid, ERK1/2 inhibition caused a major shift in the lipoprotein distribution with a majority of particles secreted as VLDL, an effect independent of insulin. In contrast, overexpression of constitutively active MEK1 decreased apoB and large VLDL secretion. MEK1/2 inhibition significantly increased both cellular and microsomal TG mass, and mRNA levels for DGAT-1 and DGAT-2. In contrast to ERK, modulation of the PI3-K pathway or inhibition of the p38 MAP kinase, had no effect on lipoprotein density profile. Modulation of the MEK–ERK pathway in primary hamster hepatocytes led to changes in apoB secretion and altered the density profile of apoB-containing lipoproteins.

Conclusion— Inhibition of the overactive ras-MEK–ERK pathway in HepG2 cells can correct the defect in VLDL assembly leading to the secretion of large, VLDL-sized particles, similar to primary hepatocytes, implicating the MEK–ERK cascade in VLDL assembly in the HepG2 model. Modulation of this pathway in primary hepatocytes also regulates apoB secretion and appears to alter the formation of VLDL-1 sized particles.

Inhibition of the overactive ras-MEK–ERK pathway in HepG2 cells was found to correct the defect in VLDL assembly (that normally secrete immature triglyceride-poor LDL-sized apoB particles) leading to the secretion of large, VLDL-sized particles, similar to primary hepatocytes. Our data implicate the MEK–ERK pathway in regulating the VLDL assembly process in HepG2 cells.

Key Words: apolipoprotein B100 • MEK–ERK • HepG2 • VLDL

This article has been cited by other articles:

				A. R. Turkish and S. L. Sturley The genetics of neutral lipid biosynthesis: an evolutionary perspective Am J Physiol Endocrinol Metab, July 1, 2009; 297(1): E19 - E27. [Abstract] [Full Text] [PDF]

				J. Tsai, R. Zhang, W. Qiu, Q. Su, M. Naples, and K. Adeli Inflammatory NF-{kappa}B activation promotes hepatic apolipoprotein B100 secretion: evidence for a link between hepatic inflammation and lipoprotein production Am J Physiol Gastrointest Liver Physiol, June 1, 2009; 296(6): G1287 - G1298. [Abstract] [Full Text] [PDF]

				A. C. Rutledge, W. Qiu, R. Zhang, R. Kohen-Avramoglu, N. Nemat-Gorgani, and K. Adeli Mechanisms Targeting Apolipoprotein B100 to Proteasomal Degradation: Evidence That Degradation Is Initiated by BiP Binding at the N Terminus and the Formation of a p97 Complex at the C Terminus Arterioscler Thromb Vasc Biol, April 1, 2009; 29(4): 579 - 585. [Abstract] [Full Text] [PDF]

				H. N. Ginsberg and E. A. Fisher The ever-expanding role of degradation in the regulation of apolipoprotein B metabolism J. Lipid Res., April 1, 2009; 50(Supplement): S162 - S166. [Abstract] [Full Text] [PDF]

				M. Asahina, W. Haruyama, Y. Ichida, M. Sakamoto, M. Sato, and K. Imaizumi Identification of SMEK2 as a candidate gene for regulation of responsiveness to dietary cholesterol in rats J. Lipid Res., January 1, 2009; 50(1): 41 - 46. [Abstract] [Full Text] [PDF]

				C.-L. E. Yen, S. J. Stone, S. Koliwad, C. Harris, and R. V. Farese Jr. Thematic Review Series: Glycerolipids. DGAT enzymes and triacylglycerol biosynthesis J. Lipid Res., November 1, 2008; 49(11): 2283 - 2301. [Abstract] [Full Text] [PDF]

				R. L. Walzem, R. A. Baillie, M. Wiest, R. Davis, S. M. Watkins, T. E. Porter, J. Simon, and L. A. Cogburn Functional Annotation of Genomic Data with Metabolic Inference Poult. Sci., July 1, 2007; 86(7): 1510 - 1522. [Abstract] [Full Text] [PDF]